| CAS ID: | 50-02-2 |
| Molecular Formula: | C22H29FO5 |
| Molecular Weight: | 392.5 g/mol |
| Monoisotopic Mass: | 392.1999 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | Dexacen-4 | DEXAMETHASONE METASULFOBENZOATE SODIUM | Dexacort | DEXACORTISYL | MAXITROL | Kortico Injection | GPPE EAR SPY | Mymethasone | OTOMIZE | SOFRADEX | DECASPRAY | DEXAFREE | DEXAMETHASONE INTENSOL | MARTAPAN | MAXIDEX | OZURDEX | DEXONE | DEXONE 0.5 | Dalalone | HEXADROL | TOBRADEX | AEROSEB-DEX | DECADERM | DEXAMETHASONE | DEXAMETHASONE PALMITATE | DEXONE 0.75 | ORADEXON | DECADRON | DECADRON-75 | DEXAMETHASONE VALERATE | SPERSADEX COMP | Neodecadron | Dexair | Decadron-LA | DEXSOL | DEXONE 4 | DEXONE 1.5 | FLUORMETHYLPREDNISOLONE | DROPODEX |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1 | See All |
| InChI Key: | UREBDLICKHMUKA-CXSFZGCWSA-N | |
| Smiles: | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO | See All |
| Molfile: | Download |
Reference Record 1
| PubMed ID | 12414515 | Target ID | |
| Uniprot ID | Name | ||
| Model | rat | Fibrosis Disease | Renal fibrosis |
| Process I | attenue inflammation | ||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Reference Record 2
| PubMed ID | 26714197 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro | Fibrosis Disease | Cystic fibrosis |
| Process I | attenue inflammation | ||
| Process II | |||
| Process III | |||
| Mechanism | Targeting IL-1 | ||
Trial Record 1
| ClinicalTrial ID | NCT01917877 | Disease | Pulmonary fibrosis |
| Phase | Phase 2 | Status | Recruiting |
| First Received | August 7, 2013 | Last Verified | February 14, 2018 |
| Sponsor | Qingdao Central Hospital | ||
Trial Record 2
| ClinicalTrial ID | NCT01311167 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Terminated |
| First Received | March 9, 2011 | Last Verified | April 18, 2013 |
| Sponsor | University Hospital Inselspital, Berne | ||
Trial Record 3
| ClinicalTrial ID | NCT03239964 | Disease | Keloid |
| Phase | Phase 4 | Status | Completed |
| First Received | August 4, 2017 | Last Verified | November 5, 2018 |
| Sponsor | Kasr El Aini Hospital | ||
| PubChem: | 5743 |
| ChEMBL: | CHEMBL384467 |